Header Logo

Connection

Naoko Takebe to Vascular Endothelial Growth Factor A

Back to Details
This is a "connection" page, showing publications Naoko Takebe has written about Vascular Endothelial Growth Factor A.
Naoko Takebe
Connection Strength
0.177
Vascular Endothelial Growth Factor A
  1. Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. Clin Cancer Res. 2022 01 15; 28(2):279-288.
    View in: PubMed
    Score: 0.177
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.